MX2009002310A - Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas. - Google Patents

Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas.

Info

Publication number
MX2009002310A
MX2009002310A MX2009002310A MX2009002310A MX2009002310A MX 2009002310 A MX2009002310 A MX 2009002310A MX 2009002310 A MX2009002310 A MX 2009002310A MX 2009002310 A MX2009002310 A MX 2009002310A MX 2009002310 A MX2009002310 A MX 2009002310A
Authority
MX
Mexico
Prior art keywords
solvent
benzodiazepine
present
clonazepam
methods
Prior art date
Application number
MX2009002310A
Other languages
English (en)
Spanish (es)
Inventor
Gene Jamieson
Michael Des Jardin
Clark Allphin
Sigridur Olafsdottir
Original Assignee
Jazz Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38819711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009002310(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jazz Pharmaceuticals Inc filed Critical Jazz Pharmaceuticals Inc
Publication of MX2009002310A publication Critical patent/MX2009002310A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2009002310A 2006-08-28 2007-08-27 Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas. MX2009002310A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84056806P 2006-08-28 2006-08-28
PCT/US2007/018877 WO2008027357A2 (en) 2006-08-28 2007-08-27 Pharmaceutical compositions of clonazepam and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2009002310A true MX2009002310A (es) 2009-09-21

Family

ID=38819711

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009002310A MX2009002310A (es) 2006-08-28 2007-08-27 Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas.

Country Status (17)

Country Link
US (2) US8716279B2 (enExample)
EP (2) EP2068933A2 (enExample)
JP (2) JP2010502614A (enExample)
KR (1) KR20090043603A (enExample)
CN (1) CN101528261B (enExample)
AR (1) AR062556A1 (enExample)
AU (1) AU2007290589B2 (enExample)
BR (1) BRPI0714907A2 (enExample)
CA (1) CA2662197A1 (enExample)
IL (1) IL197275A0 (enExample)
MX (1) MX2009002310A (enExample)
NO (1) NO20091211L (enExample)
NZ (2) NZ575744A (enExample)
PE (1) PE20081361A1 (enExample)
TW (1) TW200824693A (enExample)
UY (1) UY30561A1 (enExample)
WO (2) WO2008027395A2 (enExample)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11839597B2 (en) 2016-07-22 2023-12-12 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200824693A (en) 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
CA2676010C (en) * 2007-01-19 2016-05-17 Hananja Ehf Methods and compositions for the delivery of a therapeutic agent
US20080275030A1 (en) * 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
GB0716907D0 (en) * 2007-08-31 2007-10-10 Archimedes Dev Ltd Pharmaceutical powder compositions
US8946208B2 (en) 2007-08-31 2015-02-03 Archimedes Development Limited Non-aqueous pharmaceutical composition
EP2271347B1 (en) 2008-03-28 2016-05-11 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
KR101517415B1 (ko) * 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
WO2010126970A1 (en) * 2009-04-28 2010-11-04 Optmed, Inc. Methods for treating and preventing erectile dysfunction
WO2010126963A1 (en) * 2009-04-28 2010-11-04 Optmed, Inc. Compositions and methods for treating and preventing overactive bladder and conditions associated therewith
GB2481407B (en) * 2010-06-22 2012-05-23 Special Products Ltd A rapid onset liquid midazolam composition for buccal administration
RU2018135967A (ru) * 2011-03-31 2018-11-14 Акорда Терапьютикс, Инк. Интраназальные фармацевтические композиции на основе бензодиазепина
EP3415139B8 (en) 2011-06-14 2022-05-18 Neurelis, Inc. Administration of benzodiazepine
BR112014019171A8 (pt) 2011-12-11 2017-07-11 Recro Pharma Inc Composições intranasais de dexdetomida e seus métodos de uso
US9125805B2 (en) * 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US8999393B1 (en) * 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
EP2958594A4 (en) * 2013-02-22 2017-03-01 Eastgate Pharmaceuticals Inc. Pharmaceutical composition for enhanced transmucosal administration of benzodiazepines
KR101635635B1 (ko) * 2014-12-04 2016-07-01 주식회사 엘지생활건강 디팔미토일 하이드록시프롤린과 갈릭산 에스터 유도체를 함유하는 화장료 조성물
WO2016191413A1 (en) 2015-05-25 2016-12-01 Iso Therapeutics Group, Llc Dotmp kit formulations for radioisotopes
HUE064864T2 (hu) * 2016-12-09 2024-04-28 Alexza Pharmaceuticals Inc Az alprazolam alkalmazása epilepszia kezelésében
MX2020005169A (es) * 2017-11-17 2020-12-03 Neurana Pharmaceuticals Inc Métodos de administración de tolperisona.
US11278492B2 (en) 2018-01-05 2022-03-22 Impel Neuropharma, Inc. Intranasal delivery of olanzapine by precision olfactory device
US10896106B2 (en) 2018-05-10 2021-01-19 Teradyne, Inc. Bus synchronization system that aggregates status
US20200338090A1 (en) * 2019-04-29 2020-10-29 Marsh and Wang Medical Systems, LLC Seizure control compositions and methods of using same
CN110420190B (zh) * 2019-08-29 2021-07-09 湖南洞庭药业股份有限公司 氯硝西泮片及其制备方法
EP4351586A4 (en) * 2021-06-10 2025-04-02 Neurelis, Inc. Methods and compositions for treating seizure disorders in pediatric patients
CN115707451A (zh) * 2021-08-19 2023-02-21 北京万全德众医药生物技术有限公司 氯硝西泮口服溶液
CN114656410A (zh) * 2022-03-02 2022-06-24 济南同路医药科技发展有限公司 一种氯硝西泮杂质及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266466A (en) * 1987-01-14 1993-11-30 President And Fellows Of Harvard College Method of using T7 DNA polymerase to label the 3' end of a DNA molecule
SE8800080L (sv) 1988-01-13 1989-07-14 Kabivitrum Ab Laekemedelskomposition
US4950664A (en) 1988-09-16 1990-08-21 Rugby-Darby Group Companies, Inc. Nasal administration of benzodiazepine hypnotics
FR2656303B1 (fr) 1989-12-26 1994-06-10 Parke Davis Solution buvable d'un derive des benzodiazepines et son application pharmacologique.
ATE164080T1 (de) * 1990-05-10 1998-04-15 Bechgaard Int Res Pharmazeutische zubereitung enthaltend n- glykofurole und n-äthylenglykole
DE4021263C2 (de) 1990-07-04 1996-04-11 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung für Medien
FR2692174B1 (fr) 1992-06-16 1994-08-19 Valois Dispositif à gaz comprimé pour projeter sous forme finement divisée une dose unique d'une substance fluide.
DK17093D0 (da) 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
WO1995029678A1 (en) * 1994-04-28 1995-11-09 F.Hoffmann-La Roche Ag Pharmaceutical composition for transdermal delivery
GB9409778D0 (en) 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US20050163719A1 (en) 1997-10-01 2005-07-28 Dugger Harry A.Iii Buccal, polar and non-polar spray containing diazepam
DE19756442A1 (de) 1997-12-18 1999-06-24 Pfeiffer Erich Gmbh & Co Kg Spender für Medien
US6699849B1 (en) * 1998-02-23 2004-03-02 Cyclops, Ehf. Cyclodextrin complexes of benzodiazepines
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
GB9826192D0 (en) 1998-12-01 1999-01-20 Controlled Theraputics Scotlan Oral transmucosal delivery
EP1196156B1 (en) * 1999-07-26 2008-04-30 SK Holdings Co., Ltd. Transnasal anticonvulsive compositions
DE19938798A1 (de) 1999-08-16 2001-03-01 Pfeiffer Erich Gmbh & Co Kg Spender für Flüssigkeiten oder für zähflüssige oder versprühbare Produkte
DE19940236A1 (de) 1999-08-25 2001-03-08 Pfeiffer Erich Gmbh & Co Kg Spender mit manuell betätigbarer Ausbringeinrichtung
US6610271B2 (en) 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
WO2002011768A1 (en) 2000-08-03 2002-02-14 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
FR2815611B1 (fr) 2000-10-23 2003-04-11 Valois Sa Tete de distribution et distributeur de produit fluide comportant une telle tete de distribution
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
CA2456754A1 (en) * 2001-08-08 2003-02-20 Yuji Iizawa Benzazepine derivative, process for producing the same, and use
WO2003070273A1 (en) 2002-02-25 2003-08-28 Lyfjathroun Hf A bioadhesive agent
US6742677B2 (en) 2002-04-18 2004-06-01 Valois S.A.S. Fluid dispenser pump
CA2486909A1 (en) * 2002-05-23 2003-12-04 Umd, Inc. Compositions and method for transmucosal drug delivery and cryoprotection
ITRM20020357A1 (it) 2002-07-03 2004-01-05 Foscama Biomed Chim Farma Composizione liquida per la somministrazione orale di lorazepam.
US6855332B2 (en) 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
NZ541167A (en) 2003-01-31 2008-07-31 Orexo Ab A rapid-acting pharmaceutical composition comprising e.g. fentanyl and particles insoluble in water
WO2004110403A1 (en) 2003-06-17 2004-12-23 Sk Corporation Transnasal microemulsions containing diazepam
ATE534373T1 (de) * 2003-10-10 2011-12-15 Antares Pharma Ipl Ag Transdermale pharmazeutische formulierung zur minimierung von rückständen auf der haut
WO2006075125A1 (en) 2005-01-14 2006-07-20 Camurus Ab GnRH ANALOGUE FORMULATIONS
US20070021411A1 (en) 2005-05-11 2007-01-25 Cloyd James C Supersaturated benzodiazepine solutions and their delivery
TW200824693A (en) 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
US9319244B2 (en) 2010-12-22 2016-04-19 Usablenet Inc. Methods for emailing labels as portable data files and devices thereof

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12115145B2 (en) 2016-07-22 2024-10-15 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12115142B2 (en) 2016-07-22 2024-10-15 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11766418B2 (en) 2016-07-22 2023-09-26 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12263150B2 (en) 2016-07-22 2025-04-01 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11826335B2 (en) 2016-07-22 2023-11-28 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11839597B2 (en) 2016-07-22 2023-12-12 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11896572B2 (en) 2016-07-22 2024-02-13 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12097176B2 (en) 2016-07-22 2024-09-24 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12097175B2 (en) 2016-07-22 2024-09-24 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12109186B2 (en) 2016-07-22 2024-10-08 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12115143B2 (en) 2016-07-22 2024-10-15 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12115144B2 (en) 2016-07-22 2024-10-15 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12263151B2 (en) 2016-07-22 2025-04-01 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12128021B1 (en) 2016-07-22 2024-10-29 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12138239B2 (en) 2016-07-22 2024-11-12 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12144793B2 (en) 2016-07-22 2024-11-19 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12257223B2 (en) 2016-07-22 2025-03-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12239625B2 (en) 2016-07-22 2025-03-04 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186298B2 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12226389B2 (en) 2016-07-22 2025-02-18 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12226388B2 (en) 2016-07-22 2025-02-18 Flamel Ireland Limited Modified release gamma- hydroxybutyrate formulations having improved pharmacokinetics
US12226377B2 (en) 2019-03-01 2025-02-18 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US12167992B2 (en) 2019-03-01 2024-12-17 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US12167991B2 (en) 2019-03-01 2024-12-17 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US12303478B2 (en) 2019-03-01 2025-05-20 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12295926B1 (en) 2022-02-07 2025-05-13 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Also Published As

Publication number Publication date
US20080070904A1 (en) 2008-03-20
US20080076761A1 (en) 2008-03-27
EP2068933A2 (en) 2009-06-17
WO2008027395A2 (en) 2008-03-06
AR062556A1 (es) 2008-11-19
WO2008027357A3 (en) 2008-04-17
TW200824693A (en) 2008-06-16
IL197275A0 (en) 2009-12-24
AU2007290589B2 (en) 2012-04-05
WO2008027357A2 (en) 2008-03-06
BRPI0714907A2 (pt) 2014-08-19
US8716279B2 (en) 2014-05-06
JP2010502612A (ja) 2010-01-28
WO2008027357A9 (en) 2009-04-30
NZ575744A (en) 2011-10-28
KR20090043603A (ko) 2009-05-06
PE20081361A1 (es) 2008-11-06
CN101528261A (zh) 2009-09-09
NZ595388A (en) 2011-12-22
JP2010502614A (ja) 2010-01-28
AU2007290589A1 (en) 2008-03-06
US8609651B2 (en) 2013-12-17
WO2008027395A3 (en) 2008-04-17
CN101528261B (zh) 2012-07-18
NO20091211L (no) 2009-05-27
CA2662197A1 (en) 2008-03-06
UY30561A1 (es) 2008-03-31
EP2056877A2 (en) 2009-05-13

Similar Documents

Publication Publication Date Title
MX2009002310A (es) Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas.
IL182417A0 (en) Mitotic kinesin inhibitors and methods of use thereof
WO2005103041A3 (en) Treatment of cns disorders using cns target modulators
WO2007143607A3 (en) Method of treating atrophic vaginitis
MX2009009591A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
MX2009006339A (es) Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
MX2009006823A (es) Formas de dosificacion solidas de desintegracion oral que comprenden progestina y metodos para hacer y usar las mismas.
UA92636C2 (en) Tetrahydro-pyrimidoazepines as modulators of trpv1
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
MX2009003911A (es) Formulaciones de liberacion inmediata, mejoradas de topiramato.
MX2009010127A (es) Compuestos utiles como inhibidores de janus cinasas.
BR112012008238A2 (pt) métodos para prevenção ou tratamento de sarcopenia e atrofia muscular em animais.
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
IL193252A0 (en) N-hydroxyacrylamide compounds
MY160560A (en) Compositions and methods for treatment of kidney disorders
WO2009045992A3 (en) C-met protein kinase inhibitors
BRPI0506970B8 (pt) derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior
WO2008155390A3 (en) Use of inhibitors of sirtuins and/or ampk for the preparation of a medicament for the treatment of polyalanine diseases.
WO2008073779A3 (en) Compositions and methods for treating seizures
WO2008057496A3 (en) Method for treating delirium
PL2020999T3 (pl) Kompozycje zawierające alfa-ketoglutaran i ich zastosowanie do modulowania wydajności mięśniowej
TW200716153A (en) Mitotic kinesin inhibitors and methods of use thereof
MX2008016520A (es) Medicamentos.
WO2007149816A3 (en) Strontium compositions and methods of treating osteoporotic conditions

Legal Events

Date Code Title Description
FA Abandonment or withdrawal